At Medicine Association 2026, Wegovy Showed Greater Weight Loss Potential than Orforglipron

The upcoming Obesity Medicine Association’s annual conference in San Diego will witness significant research on obesity-control drugs. The leading player, Novo Nordisk, will present the ORION study at this conference. It is planned to show that Wegovy tablet 25 mg was related to a significantly greater mean weight loss when compared with the Orforglipron 36 mg in a population-adjusted area. It is crucial to know that the FDA has just approved orforglipron with the brand name Foundayo with doses ranging up to 17.2 mg. Moreover, in a patient preference study, adults with obesity showed a greater preference for oral tablets or medications with a semaglutide-like profile. These findings provide potential differentiation and offer valuable insights to inform clinical decisions.

According to Precedence Research, the amylin analog drugs market size accounted for USD 3.20 billion in 2025 and is predicted to increase from USD 3.47 billion in 2026 to approximately USD 7.10 billion by 2035, expanding at a CAR of 8.30% from 2026 to 2035 as it offers excellent tolerability and muscle prevention while managing obesity, rising cases of metabolic disorders and long acting agents.

A vice president, U.S. operations of Novo Nordisk, Mr. Jamey Millar stated, “These studies add to the growing body of evidence supporting the clinical strength of semaglutide and highlight attributes that patients value when choosing an obesity medicine that fits their lifestyle. Since its approval, we've seen strong interest in the Wegovy pill from both healthcare professionals and people seeking obesity therapy, underscoring the importance of our continued focus on advancing obesity care through our relentless pursuit of innovation."

A recent report by Precedence Research highlights that the amylin analog drugs market is benefiting from the shift to long-acting weekly dosing, high efficacy of next gen compounds and rising demand for combination therapies to control weight gain safely.